Citations (89)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Alessandro Mega, Aman Mebrahtu, Gustav Aniander, Eva Ryer, Annette Sköld, Anna Sandegren, Eva Backström Rydin, Johan Rockberg, Arne Östman & Fredrik Y. Frejd. (2023) A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation. mAbs 15:1.
Read now
Read now
Barbara Geerinckx, Laure-Anne Teuwen, Tiffany Foo, Timon Vandamme, Annabel Smith, Marc Peeters & Timothy Price. (2023) Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Expert Review of Anticancer Therapy 23:12, pages 1237-1249.
Read now
Read now
Xin Fan, Jianxiong Song, Yating Fan, Jiaqi Li, Yutao Chen, Huanhuan Zhu & Zhiyuan Zhang. (2021) CSMD1 Mutation Related to Immunity Can Be Used as a Marker to Evaluate the Clinical Therapeutic Effect and Prognosis of Patients with Esophageal Cancer. International Journal of General Medicine 14, pages 8689-8710.
Read now
Read now
Karin Enell Smith, Adnan Deronic, Karin Hägerbrand, Per Norlén & Peter Ellmark. (2021) Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opinion on Biological Therapy 21:12, pages 1635-1646.
Read now
Read now
Amit Sharma, Hongde Liu, Martina C. Herwig-Carl, Tikam Chand Dakal & Ingo G H Schmidt-Wolf. (2021) Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers. Cancer Investigation 39:3, pages 257-273.
Read now
Read now
Qing Lv, Yansong Liu, Hu Huang, Mingjie Zhu, Junqiang Wu & Dong Meng. (2020) Identification of Potential Key Genes and Pathways for Inflammatory Breast Cancer Based on GEO and TCGA Databases. OncoTargets and Therapy 13, pages 5541-5550.
Read now
Read now
Sahana Kumar, Anujan Ramesh & Ashish Kulkarni. (2020) Targeting macrophages: a novel avenue for cancer drug discovery. Expert Opinion on Drug Discovery 15:5, pages 561-574.
Read now
Read now
David M. Richards, Julian P. Sefrin, Christian Gieffers, Oliver Hill & Christian Merz. (2020) Concepts for agonistic targeting of CD40 in immuno-oncology. Human Vaccines & Immunotherapeutics 16:2, pages 377-387.
Read now
Read now
Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues & Anna Dimberg. (2020) Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy. OncoImmunology 9:1.
Read now
Read now
Alessia Spagnuolo & Cesare Gridelli. (2019) Combining immunotherapies to treat non-small cell lung cancer. Expert Review of Respiratory Medicine 13:7, pages 621-634.
Read now
Read now
Veethika Pandey & Peter Storz. (2019) Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma. Expert Review of Anticancer Therapy 19:6, pages 473-482.
Read now
Read now
Mariona Cabo, Rienk Offringa, Laurence Zitvogel, Guido Kroemer, Aura Muntasell & Lorenzo Galluzzi. (2017) Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. OncoImmunology 6:12.
Read now
Read now
Articles from other publishers (77)
Max M. Wattenberg, Heather CohoVeronica M. Herrera, Kathleen GrahamMeredith L. Stone, Yuqing Xue, Renee B. Chang, Christopher CassellaMingen Liu, Shaanti Choi-BoseStacy K. Thomas, Hana Choi, Yan Li, Kelly Markowitz, Lauren MelendezMichael Gianonne, Nandita BoseGregory L. Beatty. (2023) Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Science Immunology 8:89.
Crossref
Crossref
Zinab O. Doha & Rosalie C. Sears. (2023) Unraveling MYC’s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance. Pathophysiology 30:3, pages 400-419.
Crossref
Crossref
Ying Kang, Emmanuel Boadi Amoafo, Philomena Entsie, Gregory L. Beatty & Elisabetta Liverani. (2023) A role for platelets in metabolic reprogramming of tumor-associated macrophages. Frontiers in Physiology 14.
Crossref
Crossref
Luc Ollivier, Camille Moreau Bachelard, Emmanuelle Renaud, Estelle Dhamelincourt & Francois Lucia. (2023) The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review. Frontiers in Immunology 14.
Crossref
Crossref
Juan Ye, Herui Wang, Rogelio Medina, Samik Chakraborty, Mitchell Sun, Alex Valenzuela, Xueyu Sang, Yaping Zhang, Ondrej Uher, Jan Zenka, Karel Pacak & Zhengping Zhuang. (2023) rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Crossref
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Thomas F Gajewski, Martin Gutierrez, Hun Ju Lee, Ajay K Gopal, Paolo Caimi, Elisabeth I Heath, John A Thompson, Sahar Ansari, Celine Jacquemont, Ariel Topletz-Erickson, Peigen Zhou, Michael W Schmitt & Juneko E Grilley-Olson. (2023) Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas. Journal for ImmunoTherapy of Cancer 11:6, pages e005584.
Crossref
Crossref
Akansha Singh & Ashish Ranjan. (2023) Adrenergic receptor signaling regulates the CD40-receptor mediated anti-tumor immunity. Frontiers in Immunology 14.
Crossref
Crossref
Hsuan‐Chen Liu, Daniel Davila Gonzalez, Dixita Ishani Viswanath, Robin Shae Vander Pol, Shani Zakiya Saunders, Nicola Di Trani, Yitian Xu, Junjun Zheng, Shu‐Hsia Chen, Corrine Ying Xuan Chua & Alessandro Grattoni. (2023) Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Advanced Science 10:9.
Crossref
Crossref
Scott Parker, Charlotte McDowall, Luis Sanchez-PerezCristina Osorio, Patrick C. Duncker, Aaron BrileyAdam M. SwartzJames E. HerndonIIIIYen-Rei A. YuRoger E. McLendon, Thomas F. Tedder, Annick Desjardins, David M. AshleyMichael Dee Gunn, David S. Enterline, David A. Knorr, Ira H. Pastan, Smita K. Nair, Darell D. Bigner & Vidyalakshmi Chandramohan. (2023) Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science Translational Medicine 15:682.
Crossref
Crossref
Mara H. ShermanGregory L. Beatty. (2023) Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annual Review of Pathology: Mechanisms of Disease 18:1, pages 123-148.
Crossref
Crossref
Marc Pfefferlé, Irina L Dubach, Raphael M Buzzi, Elena Dürst, Nadja Schulthess-Lutz, Livio Baselgia, Kerstin Hansen, Larissa Imhof, Sandra Koernig, Didier Le Roy, Thierry Roger, Rok Humar, Dominik J Schaer & Florence Vallelian. (2023) Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity. Journal for ImmunoTherapy of Cancer 11:1, pages e005718.
Crossref
Crossref
Mengmeng Liu, Lina Liu, Yongping Song, Wei Li & Linping Xu. (2022) Targeting macrophages: a novel treatment strategy in solid tumors. Journal of Translational Medicine 20:1.
Crossref
Crossref
Xavier Chauchet, Laura Cons, Laurence Chatel, Bruno Daubeuf, Gérard Didelot, Valéry Moine, Didier Chollet, Pauline Malinge, Guillemette Pontini, Krzysztof Masternak, Walter Ferlin, Vanessa Buatois & Limin Shang. (2022) CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Karin Hägerbrand, Laura Varas, Adnan Deronic, Barnabas Nyesiga, Anette Sundstedt, Lill Ljung, Christina Sakellariou, Doreen Werchau, Mia Thagesson, David Gomez Jimenez, Lennart Greiff, Mona Celander, Kristine Smedenfors, Anna Rosén, Deniz Bölükbas, Fredrika Carlsson, Mattias Levin, Anna Säll, Laura von Schantz, Malin Lindstedt & Peter Ellmark. (2022) Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. Journal for ImmunoTherapy of Cancer 10:11, pages e005018.
Crossref
Crossref
Nicholas A. Ullman, Paul R. Burchard, Richard F. Dunne & David C. Linehan. (2022)
Immunologic Strategies in Pancreatic Cancer: Making
Cold
Tumors
Hot
. Journal of Clinical Oncology 40:24, pages 2789-2805.
Crossref
Crossref
Xuejiao Li, Huan Du, Shenghua Zhan, Wenting Liu, Zhangyu Wang, Jing Lan, Longxiang PuYang, Yuqiu Wan, Qiuxia Qu, Sining Wang, Yang Yang, Qin Wang & Fang Xie. (2022) The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. Frontiers in Immunology 13.
Crossref
Crossref
Ling Peng, Zibing Wang, Justin Stebbing & Zhentao Yu. (2022) Novel immunotherapeutic drugs for the treatment of lung cancer. Current Opinion in Oncology 34:1, pages 89-94.
Crossref
Crossref
Timothy N. J. Bullock. (2021) CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies. Cellular & Molecular Immunology 19:1, pages 14-22.
Crossref
Crossref
Chi Yan, Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau-Chiann Chen, Rebecca L. Shattuck-Brandt, Gregory D. Ayers & Ann Richmond. (2021) Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. Molecular Cancer 20:1.
Crossref
Crossref
Khosrow Kashfi, Jasmine Kannikal & Niharika Nath. (2021) Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO. Cells 10:11, pages 3194.
Crossref
Crossref
Meredith L. Stone, Jesse Lee, Veronica M. Herrera, Kathleen Graham, Jae W. Lee, Austin Huffman, Heather Coho, Evan Tooker, Max I. Myers, Michael Giannone, Yan Li, Thomas H. Buckingham, Kristen B. Long & Gregory L. Beatty. (2021) TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. JCI Insight 6:14.
Crossref
Crossref
Sadaf Aghevlian, Bo Wu, Marina Nura Raie, Spencer K. Tumbale, Aris J. Kare, Jai W. Seo & Katherine W. Ferrara. (2021) Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice. Nuclear Medicine and Biology 98-99, pages 8-17.
Crossref
Crossref
Erin L. Filbert, Pia K. Björck, Minu K. Srivastava, Frances R. Bahjat & Xiaodong Yang. (2021) APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunology, Immunotherapy 70:7, pages 1853-1865.
Crossref
Crossref
Mansi Saxena, Sjoerd H. van der Burg, Cornelis J. M. Melief & Nina Bhardwaj. (2021) Therapeutic cancer vaccines. Nature Reviews Cancer 21:6, pages 360-378.
Crossref
Crossref
Christopher S. Garris, Jeffrey L. Wong, Jeffrey V. Ravetch & David A. Knorr. (2021) Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science Translational Medicine 13:594.
Crossref
Crossref
Julian A. Marin-Acevedo, ErinMarie O. Kimbrough, Rami Manochakian, Yujie Zhao & Yanyan Lou. (2021) Immunotherapies targeting stimulatory pathways and beyond. Journal of Hematology & Oncology 14:1.
Crossref
Crossref
Laurence P. Diggs, Benjamin Ruf, Chi Ma, Bernd Heinrich, Linda Cui, Qianfei Zhang, John C. McVey, Simon Wabitsch, Sophia Heinrich, Umberto Rosato, Walter Lai, Varun Subramanyam, Thomas Longerich, Sven H. Loosen, Tom Luedde, Ulf Peter Neumann, Sabina Desar, David Kleiner, Gregory Gores, Xin Wei Wang & Tim F. Greten. (2021) CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology 74:5, pages 1145-1154.
Crossref
Crossref
Cecilia Roux, Gianluca Mucciolo, Joanna Kopecka, Francesco Novelli, Chiara Riganti & Paola Cappello. (2021) IL17A Depletion Affects the Metabolism of Macrophages Treated with Gemcitabine. Antioxidants 10:3, pages 422.
Crossref
Crossref
Max M. Wattenberg, Veronica M. Herrera, Michael A. Giannone, Whitney L. Gladney, Erica L. Carpenter & Gregory L. Beatty. (2021) Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients. JCI Insight 6:5.
Crossref
Crossref
Liping Xu, Xiaoli Xie & Ying Luo. (2021) The role of macrophage in regulating tumour microenvironment and the strategies for reprogramming tumour-associated macrophages in antitumour therapy. European Journal of Cell Biology 100:2, pages 151153.
Crossref
Crossref
Eileen Carpenter, Sarah Nelson, Filip Bednar, Clifford Cho, Hari Nathan, Vaibhav Sahai, Marina Pasca di Magliano & Timothy L. Frankel. (2021) Immunotherapy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology 123:3, pages 751-759.
Crossref
Crossref
Srikrishnan Rameshbabu, Brian W. Labadie, Anna Argulian & Akash Patnaik. (2021) Targeting Innate Immunity in Cancer Therapy. Vaccines 9:2, pages 138.
Crossref
Crossref
Jason J Luke, Fabrice Barlesi, Ki Chung, Anthony W Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Philippe A Cassier, Mustafa Khasraw, Hedy L Kindler, Hua Fang, Frances Fan, Kathryn Allaire, Maulik Patel, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt & Lawrence Fong. (2021) Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer 9:2, pages e002015.
Crossref
Crossref
Soo-Bin Yang, Mi-Hyun Lee, Bo-Ram Kim, Yu-Min Choi & Bum-Joon Kim. (2021) A Hepatitis B Virus-Derived Peptide Exerts an Anticancer Effect via TNF/iNOS-producing Dendritic Cells in Tumor-Bearing Mouse Model. Cancers 13:3, pages 407.
Crossref
Crossref
Michele Ghidini, Andrea Lampis, Milko B. Mirchev, Ali Fuat Okuducu, Margherita Ratti, Nicola Valeri & Jens C. Hahne. (2020) Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes 12:1, pages 33.
Crossref
Crossref
Richard Lee Barrett & Ellen Puré. (2020) Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy. eLife 9.
Crossref
Crossref
Yuanyuan Shen, Yue Guan, Justin J. Hummel, Chi-Ren Shyu & Jonathan B. Mitchem. (2020) Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer. BMC Cancer 20:1.
Crossref
Crossref
Shan He, Jinhua Xu & Jinfeng Wu. (2020) The emerging role of co-stimulatory molecules and their agonistic mAb-based combination therapies in melanoma. International Immunopharmacology 89, pages 107097.
Crossref
Crossref
Celia Jacoberger-Foissac, Stephen J Blake, Jing Liu, Elizabeth McDonald, Hannah Triscott, Kyohei Nakamura, Mark J Smyth & Michele WL Teng. (2020) Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy. Journal for ImmunoTherapy of Cancer 8:2, pages e001687.
Crossref
Crossref
Max M. Wattenberg & Gregory L. Beatty. (2020) Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Seminars in Cancer Biology 65, pages 38-50.
Crossref
Crossref
Marine M. Leblond, Laure Tillé, Sina Nassiri, Connie B. Gilfillan, Claire Imbratta, Martina Schmittnaegel, Carola H. Ries, Daniel E. Speiser & Grégory Verdeil. (2020) CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. Cancer Immunology Research 8:9, pages 1180-1192.
Crossref
Crossref
Peter Abdou, Zejun Wang, Qian Chen, Amanda Chan, Daojia R. Zhou, Vivienne Gunadhi & Zhen Gu. (2020) Advances in engineering local drug delivery systems for cancer immunotherapy. WIREs Nanomedicine and Nanobiotechnology 12:5.
Crossref
Crossref
Paweł Łaniewski, Haiyan Cui, Denise J. Roe, Dana M. Chase & Melissa M. Herbst-Kralovetz. (2020) Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment. npj Precision Oncology 4:1.
Crossref
Crossref
Giada Ingoglia, Ayla Yalamanoglu, Marc Pfefferlé, Irina L. Dubach, Christian A. Schaer, Kristyna Valkova, Kerstin Hansen, Nadja Schulthess, Rok Humar, Dominik J. Schaer & Florence Vallelian. (2020) Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice. Blood Advances 4:12, pages 2751-2761.
Crossref
Crossref
Richard Barrett & Ellen Puré. (2020) Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy. Current Opinion in Immunology 64, pages 80-87.
Crossref
Crossref
Chenshuo Luo, Ting Lei, Man Zhao, Qian Meng & Man Zhang. (2020) CD40 is Positively Correlated with the Expression of Nucleophosmin in Cisplatin-Resistant Bladder Cancer. Journal of Oncology 2020, pages 1-10.
Crossref
Crossref
Jana Wood, Sayeda Yasmin-Karim, Romy Mueller, Akila N. Viswanathan & Wilfred Ngwa. (2020) Single Radiotherapy Fraction with Local Anti-CD40 Therapy Generates Effective Abscopal Responses in Mouse Models of Cervical Cancer. Cancers 12:4, pages 1026.
Crossref
Crossref
MARINA D. MILLER & ERIC J. DEVOR. (2020) Integration of Clinical and Molecular Features into Prediction Models for Outcomes in Endometrial Cancer. Clinical Obstetrics & Gynecology 63:1, pages 40-47.
Crossref
Crossref
Lena Gaissmaier & Petros Christopoulos. (2020) Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration 99:11, pages 903-929.
Crossref
Crossref
Carla Riera-DomingoAnnette AudigéSara GranjaWan-Chen ChengPing-Chih HoFátima BaltazarChristian StockmannMassimiliano Mazzone. (2020) Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy. Physiological Reviews 100:1, pages 1-102.
Crossref
Crossref
Nicholas C. DeVito, Michael P. Plebanek, Bala Theivanthiran & Brent A. Hanks. (2019) Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. Frontiers in Immunology 10.
Crossref
Crossref
Xiaobo Liu, Yingjie Zhao, Huan Shi, Yan Zhang, Xueying Yin, Mingdong Liu, Huihui Zhang, Yongning He, Boxun Lu, Tengchuan Jin & Fubin Li. (2019) Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility. Nature Communications 10:1.
Crossref
Crossref
Meredith L. Stone & Gregory L. Beatty. (2019) Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Pharmacology & Therapeutics 201, pages 202-213.
Crossref
Crossref
Jenn-Haung Lai, Shue-Fen Luo & Ling-Jun Ho. (2019) Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis. Cells 8:8, pages 927.
Crossref
Crossref
Luca Mazzarella, Bruno Achutti Duso, Dario Trapani, Carmen Belli, Paolo D'Amico, Emanuela Ferraro, Giulia Viale & Giuseppe Curigliano. (2019) The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review. European Journal of Cancer 117, pages 14-31.
Crossref
Crossref
Nadine S. Jahchan, Adriana M. Mujal, Joshua L. Pollack, Mikhail Binnewies, Venkataraman Sriram, Leonard Reyno & Matthew F. Krummel. (2019) Tuning the Tumor Myeloid Microenvironment to Fight Cancer. Frontiers in Immunology 10.
Crossref
Crossref
Joanna Kowal, Mara Kornete & Johanna A Joyce. (2019) Re-education of macrophages as a therapeutic strategy in cancer. Immunotherapy 11:8, pages 677-689.
Crossref
Crossref
Kristen B. Long, Arthur I. Collier & Gregory L. Beatty. (2019) Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance. Molecular Immunology 110, pages 3-12.
Crossref
Crossref
Foteinos-Ioannis D. Dimitrakopoulos, Anastasia E. Kottorou, Anna G. Antonacopoulou, Nikolaos Panagopoulos, Chrisoula Scopa, Melpomeni Kalofonou, Dimitrios Dougenis, Angelos Koutras, Thomas Makatsoris, Vassiliki Tzelepi & Haralabos P. Kalofonos. (2019) Expression of Immune System-Related Membrane Receptors CD40, RANK, BAFFR and LTβR is Associated with Clinical Outcome of Operated Non-Small-Cell Lung Cancer Patients. Journal of Clinical Medicine 8:5, pages 741.
Crossref
Crossref
Vinod P. Balachandran, Gregory L. Beatty & Stephanie K. Dougan. (2019) Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Gastroenterology 156:7, pages 2056-2072.
Crossref
Crossref
Nathan Suek, Luis Felipe Campesato, Taha Merghoub & Danny N. Khalil. (2019) Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect. Frontiers in Immunology 10.
Crossref
Crossref
Hans Prenen & Massimiliano Mazzone. (2019) Tumor-associated macrophages: a short compendium. Cellular and Molecular Life Sciences 76:8, pages 1447-1458.
Crossref
Crossref
Jérôme Galon & Daniela Bruni. (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nature Reviews Drug Discovery 18:3, pages 197-218.
Crossref
Crossref
Roberto Salvia, Fabio Casciani, Elisabetta Sereni & Claudio Bassi. (2019) Pancreatic cancer – What's next?. La Presse Médicale 48:3, pages e187-e197.
Crossref
Crossref
Laura A. Vitale, Lawrence J. Thomas, Li-Zhen He, Thomas O’Neill, Jenifer Widger, Andrea Crocker, Karuna Sundarapandiyan, James R. Storey, Eric M. Forsberg, Jeffrey Weidlick, April R. Baronas, Lauren E. Gergel, James M. Boyer, Crystal Sisson, Joel Goldstein, Henry C. Marsh & Tibor Keler. (2018) Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunology, Immunotherapy 68:2, pages 233-245.
Crossref
Crossref
Grazia R. Tundo, Diego Sbardella, Pedro M. Lacal, Grazia Graziani & Stefano Marini. (2019) On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. Chemotherapy 64:2, pages 62-80.
Crossref
Crossref
Zhangguo Chen & Jing H. Wang. 2019.
105
164
.
Rachel A. Woolaver, Xiaoguang Wang, Yonatan Dollin, Ping Xie, Jing H. Wang & Zhangguo Chen. (2018) TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation. The Journal of Immunology 201:11, pages 3421-3430.
Crossref
Crossref
Corrine Ying Xuan Chua, Priya Jain, Antonia Susnjar, Jessica Rhudy, Marco Folci, Andrea Ballerini, April Gilbert, Shailbala Singh, Giacomo Bruno, Carly S. Filgueira, Cassian Yee, E. Brian Butler & Alessandro Grattoni. (2018) Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. Journal of Controlled Release 285, pages 23-34.
Crossref
Crossref
Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin, Darryn Bampton, Paul Handley, Fleur Lankesheer, Glynn Morrish, Yiping Yang, Michael P. Brown & Michael Millward. (2018) A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. British Journal of Cancer 118:8, pages 1035-1041.
Crossref
Crossref
Meher Majety, Valeria Runza, Christian Lehmann, Sabine Hoves & Carola H. Ries. (2017) A drug development perspective on targeting tumor‐associated myeloid cells. The FEBS Journal 285:4, pages 763-776.
Crossref
Crossref
Nicolas Villanueva & Lyudmila Bazhenova. (2018) New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Therapeutic Advances in Respiratory Disease 12, pages 175346661879413.
Crossref
Crossref
Meng Qiao, Tao Jiang, Shengxiang Ren & Caicun Zhou. (2018) Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer: Where Do We Stand?. Clinical Lung Cancer 19:1, pages 1-11.
Crossref
Crossref
Gennadiy Didenko, Olena Kruts, Larysa Skivka & Yuriy Prylutskyy. 2018. HSP70 in Human Diseases and Disorders. HSP70 in Human Diseases and Disorders
325
345
.
Karla R. Wiehagen, Natasha M. Girgis, Douglas H. Yamada, Andressa A. Smith, Szeman Ruby Chan, Iqbal S. Grewal, Michael Quigley & Raluca I. Verona. (2017) Combination of CD40 Agonism and CSF-1R Blockade Reconditions Tumor-Associated Macrophages and Drives Potent Antitumor Immunity. Cancer Immunology Research 5:12, pages 1109-1121.
Crossref
Crossref
Chun-Ping Liu, Xian Zhang, Qing-Long Tan, Wen-Xing Xu, Chang-Yuan Zhou, Min Luo, Xiong Li, Run-Yue Huang & Xing Zeng. (2017) NF-κB pathways are involved in M1 polarization of RAW 264.7 macrophage by polyporus polysaccharide in the tumor microenvironment. PLOS ONE 12:11, pages e0188317.
Crossref
Crossref
Gregory L. BeattyShabnam EghbaliRebecca Kim. (2017) Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. American Society of Clinical Oncology Educational Book:37, pages 267-278.
Crossref
Crossref